---
title: "Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024."
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280502605.md"
description: "From October 1, 2025 to December 31, 2025, the company has repurchased 0 shares, representing 0% for HKD 0 million. With this, the company has completed the repurchase of 102,570,847 shares, representing 0.88% for HKD 525.36 million under the buyback announced on September 19, 2024."
datetime: "2026-03-25T16:00:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280502605.md)
  - [en](https://longbridge.com/en/news/280502605.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280502605.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280502605.md) | [English](https://longbridge.com/en/news/280502605.md)


# Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.

From October 1, 2025 to December 31, 2025, the company has repurchased 0 shares, representing 0% for HKD 0 million. With this, the company has completed the repurchase of 102,570,847 shares, representing 0.88% for HKD 525.36 million under the buyback announced on September 19, 2024.

### 相關股票

- [CSPC PHARMA (01093.HK)](https://longbridge.com/zh-HK/quote/01093.HK.md)

## 相關資訊與研究

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/zh-HK/news/280415449.md)
- [CSPC Pharma Unit Files Application with HKEX for Proposed H-Share Listing](https://longbridge.com/zh-HK/news/269327436.md)
- [Seatrium Buys Back More Shares](https://longbridge.com/zh-HK/news/280408980.md)
- [CSPC Pharma Gets China Nod for Multiple Drug Trials](https://longbridge.com/zh-HK/news/270994613.md)
- [Miro's CEO says companies should treat spending on AI as part of their employee learning budget](https://longbridge.com/zh-HK/news/280016686.md)